Eisai Enters Biologics With Morphotek Buy | Chemical & Engineering News
Volume 85 Issue 14 | p. 26 | Concentrates
Issue Date: April 2, 2007

Eisai Enters Biologics With Morphotek Buy

Department: Business

The Tokyo-based drug company Eisai has agreed to pay $325 million for Morphotek, an Exton, Pa., developer of monoclonal antibody therapeutics. The deal expands Eisai's oncology drug discovery efforts beyond small molecules. In addition to Morphotek's human antibody technology platform, Eisai gains an antibody in Phase I/II trials for ovarian cancer, another drug in Phase I trials for pancreatic cancer, and a range of antibodies in preclinical studies.

 
Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society

Leave A Comment

*Required to comment